Hypera Stock Forecast, Price & News

-0.31 (-4.40 %)
(As of 06/11/2021 03:56 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5,300 shs
Average Volume12,645 shs
Market Capitalization$4.26 billion
P/E Ratio16.83
Dividend Yield2.08%
30 days | 90 days | 365 days | Advanced Chart
Receive HYPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for Hypera and its competitors with MarketBeat's FREE daily newsletter.

Hypera logo

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands; dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. The company also provides nutrition, sweeteners, and vitamin supplement products under the Tamarine, Vitasay 50+, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Torsilax, Neosoro, Doralgina, Flavonid, and Histamin brands. It sells its products through distributors and wholesalers. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.94 out of 5 stars

Medical Sector

1164th out of 2,099 stocks

Pharmaceutical Preparations Industry

534th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Hypera (OTCMKTS:HYPMY) Frequently Asked Questions

Is Hypera a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hypera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Hypera stock.
View analyst ratings for Hypera
or view top-rated stocks.

What stocks does MarketBeat like better than Hypera?

Wall Street analysts have given Hypera a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hypera wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hypera?

Hypera saw a increase in short interest in May. As of May 14th, there was short interest totaling 6,300 shares, an increase of 117.2% from the April 29th total of 2,900 shares. Based on an average daily volume of 9,100 shares, the days-to-cover ratio is currently 0.7 days.
View Hypera's Short Interest

When is Hypera's next earnings date?

Hypera is scheduled to release its next quarterly earnings announcement on Friday, July 23rd 2021.
View our earnings forecast for Hypera

How were Hypera's earnings last quarter?

Hypera S.A. (OTCMKTS:HYPMY) posted its quarterly earnings data on Friday, April, 23rd. The company reported $0.09 earnings per share (EPS) for the quarter. The company earned $214.21 million during the quarter. Hypera had a trailing twelve-month return on equity of 14.80% and a net margin of 30.68%.
View Hypera's earnings history

How has Hypera's stock been impacted by Coronavirus (COVID-19)?

Hypera's stock was trading at $6.98 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HYPMY stock has decreased by 3.6% and is now trading at $6.73.
View which stocks have been most impacted by COVID-19

Is Hypera a good dividend stock?

Hypera pays an annual dividend of $0.14 per share and currently has a dividend yield of 2.08%.
View Hypera's dividend history.

Who are Hypera's key executives?

Hypera's management team includes the following people:
  • Mr. Breno Toledo Pires de Oliveira, Chief Exec. Officer
  • Mr. Adalmario Ghovatto Satheler do Couto, Investor Relations Officer & CFO
  • Mr. Carlos Roberto Scorsi, Chief Operating officer (Age 59)
  • Juliana Aguinaga Damião Salem, Chief Legal & Compliance Officer
  • Mr. Luiz Eduardo Sales Clavis, Commercial & Marketing VP
  • Mr. Nelson José de Mello, Chief Corp. Relations Officer (Age 62)
  • Mr. Hélio Segouras, Head of Consumer Health
  • Mr. Claudio Bergamo dos Santos, Pres of Pharma & Director (Age 56)
  • Mr. Martim Prado Mattos, Sec. (Age 41)
  • Mr. Luiz Eduardo Violland, Chief Exec. Officer of the Pharmaceutical Division

Who are some of Hypera's key competitors?

What is Hypera's stock symbol?

Hypera trades on the OTCMKTS under the ticker symbol "HYPMY."

How do I buy shares of Hypera?

Shares of HYPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hypera's stock price today?

One share of HYPMY stock can currently be purchased for approximately $6.73.

How much money does Hypera make?

Hypera has a market capitalization of $4.26 billion and generates $793.81 million in revenue each year.

How many employees does Hypera have?

Hypera employs 8,918 workers across the globe.

What is Hypera's official website?

The official website for Hypera is www.hyperapharma.com.br.

Where are Hypera's headquarters?

Hypera is headquartered at AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120.

How can I contact Hypera?

Hypera's mailing address is AV. MAGALHAES DE CASTRO 4800 - 24¿ ANDAR EDIFICIO CONTINENTAL TOWER, SAO PAULO D5, 05676-120. The company can be reached via phone at 55-11-3627-4206 or via email at [email protected]

This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.